Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rentokil backs FY outlook, hails improving performance in NA

(Sharecast News) - Rentokil Initial backed its full-year outlook on Thursday as it hailed a "solid" first half, in line with expectations, and an improving performance in North America. In the six months to 30 June, adjusted pre-tax profit fell 7.8% to $418m and adjusted operating profit declined 4.5% from the same period a year earlier to $511m. This was driven mainly by reduced profitability in North America, where adjusted operating profit dropped 7.3% to $356m.

Group revenue rose 3.1% to $3.36bn. Rentokil said group organic revenue grew 1.6%. Revenue growth in North America was 2%, while the international business performed well, with revenue up 5.1% in the first half and growth across the region.

Chief executive Andy Ransom said: "Our sales and marketing initiatives in North America are starting to have an impact, with organic revenue growth of 1.4% in the second quarter up from 0.7% in the first quarter. We are refocusing our marketing budget towards driving organic lead flow and we are seeing encouraging results, including from our satellite branches, where we now have 100 in operation.

"While it is still early, we are encouraged with our progress, with residential and termite lead flow growing in June for the first time this year, up 6.6%. We are also encouraged by the early results that we are seeing from the door to door pilot that we started in the second quarter."

Random said current trading is in line with expectations and the company's outlook for the remainder of the year remains unchanged.

"We expect to deliver FY25 results in line with market expectations," he said.

At 1158 BST, the shares were 10.7% at 383.84p.

Steve Clayton, head of equity funds at Hargreaves Lansdown, said: "Rentokil Initial investors heaved a sigh of relief this morning when the group announced reassuring trading for the half year and reiterated their expectations for the remainder of the year.

"Having fallen from around the 600p level two years ago, they have been trading around the 350p level in recent weeks, so Rentokil Investors could have been forgiven for feeling like the rats were getting the better treatment.

"Today's news that there are signs of improvement in trading at the group's key US Pest division was enough to rally spirits, with investors pushing the stock as much as 12% higher."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.